Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient
Sign Up to like & getrecommendations! Published in 2019 at "IDCases"
DOI: 10.1016/j.idcr.2019.e00634
Abstract: Ceftazidime–avibactam is a combination agent consisting of the β-lactamase inhibitor avibactam and the broad-spectrum cephalosporin ceftazidime. There are no published case reports or studies evaluating the use of CAZ-AVI in pediatric critically ill patients. We… read more here.
Keywords: ceftazidime avibactam; pediatric critically; successful treatment; critically ill ... See more keywords
Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2018.07.027
Abstract: In Pseudomonas aeruginosa (P. aeruginosa) collected from cystic fibrosis (CF) patients, 24% resistance to ceftazidime-avibactam in isolates negative for carbapenemases and extended-spectrum β-lactamases (ESBLs) has previously been observed. The current study aimed to unravel the… read more here.
Keywords: ceftazidime avibactam; mexab oprm; avibactam;
In vitro activity of aztreonam-avibactam (ATM-AVI) against a global collection of Klebsiella pneumoniae, collected from defined culture sources, in 2016 and 2017.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of global antimicrobial resistance"
DOI: 10.1016/j.jgar.2020.08.004
Abstract: OBJECTIVES This study reports on the activity of aztreonam-avibactam against a collection of Klebsiella pneumoniae collected in 2016 and 2017. METHODS Non-duplicate isolates of K. pneumoniae were collected from four regions (Africa/Middle East, n=785; Asia-Pacific,… read more here.
Keywords: culture sources; aztreonam avibactam; pneumoniae collected; activity ... See more keywords
Orally Absorbed Derivatives of the β-Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.8b01389
Abstract: Only one FDA-approved β-lactamase inhibitor has ever been orally available: clavulanic acid, approved in 1984. Avibactam, approved by FDA in 2015, is the first of a new class of BLIs called diazabicyclooctanes, or "DBOs". This… read more here.
Keywords: inhibitor; clavulanic acid; lactamase inhibitor; orally absorbed ... See more keywords
Past, present, and future perspectives on aztreonam and avibactam
Sign Up to like & getrecommendations! Published in 2025 at "Expert Review of Anti-infective Therapy"
DOI: 10.1080/14787210.2025.2473047
Abstract: ABSTRACT Introduction Aztreonam is a monobactam antibiotic approved in 1986 to treat infections caused by aerobic Gram-negative bacteria, but, together with cephalosporins, lost clinical utility due to the emergence of extended-spectrum β-lactamases (ESBLs) and novel… read more here.
Keywords: aztreonam avibactam; avibactam; gram negative; present future ... See more keywords
Inhibition of &bgr;-lactamases of mycobacteria by avibactam and clavulanate
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkw546
Abstract: Objectives Mycobacterium tuberculosis and Mycobacterium abscessus produce broad-spectrum class A β-lactamases, BlaC and Bla Mab , which are inhibited by clavulanate and avibactam, respectively. BlaC differs from Bla Mab at Ambler position 132 in the… read more here.
Keywords: clavulanate; bla mab; avibactam; inhibition ... See more keywords
Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017–2022)
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaf250
Abstract: Abstract Background Carbapenem-resistant Enterobacterales (CREs) are a major public health threat because treatment options are limited. The predominant resistance mechanism in CREs is the production of carbapenemases. Aztreonam-avibactam was shown to possess activity against CREs… read more here.
Keywords: aztreonam avibactam; avibactam; resistant enterobacterales; carbapenem resistant ... See more keywords
1422. Comparative Monte-Carlo Analysis of Aztreonam-Avibactam vs. Ceftazidime–Avibactam Against Carbapenem-Resistant Gram-Negative Pathogens
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1253
Abstract: Abstract Background The new β-lactamase inhibitor, avibactam (AVI), has recently been combined with ceftazidime (CAZ) as CAZ-AVI. AVI is also in Phase 3 clinical trials combined with aztreonam as ATM-AVI. Both drug combinations have similar… read more here.
Keywords: 100 100; caz avi; atm avi; avi ... See more keywords
In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00592-18
Abstract: Enterobacteriaceae producing the Ambler class D OXA-48 carbapenemase, combined with additional resistance mechanisms, such as permeability defects or cocarriage of class A, B, or C β-lactamases, can become highly resistant to most β-lactams currently in… read more here.
Keywords: ceftazidime avibactam; methodology; aztreonam avibactam; resistance ... See more keywords
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients
Sign Up to like & getrecommendations! Published in 2025 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01950-24
Abstract: ABSTRACT Aztreonam-avibactam, a fixed-ratio (3:1) β-lactam/β-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired/ventilator-associated pneumonia, and other infections due to aerobic gram-negative organisms… read more here.
Keywords: aztreonam avibactam; population pharmacokinetic; avibactam; dose regimens ... See more keywords
Rapid ResaCeftazidime-Avibactam Enterobacterales NP Test: Rapid Detection of Ceftazidime-Avibactam Susceptibility in Enterobacterales
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Microbiology"
DOI: 10.1128/jcm.00004-22
Abstract: Ceftazidime-avibactam (CZA), a novel β-lactam/β-lactamase inhibitor combination, has good antibacterial activity against carbapenem-resistant Enterobacterales (CRE) producing class A and C and some class D carbapenemases, but in recent years, the emergence of CZA-resistant Enterobacterales bacteria… read more here.
Keywords: rapid resaceftazidime; resaceftazidime avibactam; cza; ceftazidime avibactam ... See more keywords